Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
Top Cited Papers
Open Access
- 20 March 2014
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 123 (12) , 1818-1825
Abstract
Key Points: Eltrombopag promotes hematopoiesis in patients with severe aplastic anemia by stimulating stem and progenitor cells. Eltrombopag can be discontinued safely in robust responders with maintenance of hematopoiesis.Keywords
This publication has 48 references indexed in Scilit:
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaNew England Journal of Medicine, 2012
- SNP array–based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromesBlood, 2011
- Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemiaHaematologica, 2011
- Comparative genomic hybridization on microarray (a-CGH) in constitutional and acquired mosaicism may detect as low as 8% abnormal cellsMolecular Cytogenetics, 2011
- Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two DecadesClinical Infectious Diseases, 2011
- Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromesHaematologica, 2010
- Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndromeBlood, 2009
- Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemiaBlood, 2007
- Current concepts in the pathophysiology and treatment of aplastic anemiaBlood, 2006
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989